During this segment, the panelists discuss how new agents have affected the expectations of physicians and patients in terms of overall outcomes. Unfortunately, they conclude that there is some disparity between the expectations and the reality.
Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that our country has not achieved developing a multi-target agent. While certain drugs control certain events, they often lead to other events. Additionally, while treatment with agents such as glucagon-like peptide-1 is presented as a terrific treatment option, there is still a lack in data that demonstrates that it does in fact reduce cardiovascular disease.
Kenneth L. Schaecher, MD, FACP, CPC, agrees with Dr Handelsman but does feel that a benefit of the wide range of available agents has allowed professionals to treat patients with flexibility. Rather than treating a patient off of a specific protocol, this allows patients to be treated with a more personalized therapy concept.
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More